GuideHaematology
Myelodysplastic syndrome-specific frailty index and scale (MDS-FI)
Deficit-accumulation frailty index designed for patients with myelodysplastic syndrome, adding prognostic information to the IPSS.
Updated 3 November 2026
When to use it
Patients with myelodysplastic syndrome (MDS), usually older, to complement prognostic stratification and guide treatment intensity.
What it is
Frailty index derived from the Canadian prospective MDS registry (Starkman 2020). It follows Rockwood's principle: the more deficits a person accumulates, the higher the risk of poor outcomes. It is expressed as the ratio of deficits present to deficits assessed (0 to 1).
Keep reading in the app
- Domains
- Interpretation
- Limitations
Practical tip
"MDS" here refers to myelodysplastic syndrome, not to a cardiology scale.
2 more practical tips in the app.
Reference
- Starkman R, Alibhai S, Wells RA, et al. An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia. 2020;34(5):1394-1406.
- Wan BA, Nazha A, Starkman R, et al. Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia. 2020;34(12):3434-3438.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
